1. Home
  2. AMRX vs MTSR Comparison

AMRX vs MTSR Comparison

Compare AMRX & MTSR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AMRX
  • MTSR
  • Stock Information
  • Founded
  • AMRX 2002
  • MTSR 2022
  • Country
  • AMRX United States
  • MTSR United States
  • Employees
  • AMRX N/A
  • MTSR N/A
  • Industry
  • AMRX Biotechnology: Pharmaceutical Preparations
  • MTSR
  • Sector
  • AMRX Health Care
  • MTSR
  • Exchange
  • AMRX Nasdaq
  • MTSR NYSE
  • Market Cap
  • AMRX 2.5B
  • MTSR 3.0B
  • IPO Year
  • AMRX N/A
  • MTSR 2025
  • Fundamental
  • Price
  • AMRX $8.37
  • MTSR $28.86
  • Analyst Decision
  • AMRX Strong Buy
  • MTSR Strong Buy
  • Analyst Count
  • AMRX 4
  • MTSR 6
  • Target Price
  • AMRX $11.50
  • MTSR $55.25
  • AVG Volume (30 Days)
  • AMRX 1.9M
  • MTSR 1.1M
  • Earning Date
  • AMRX 08-08-2025
  • MTSR 08-26-2025
  • Dividend Yield
  • AMRX N/A
  • MTSR N/A
  • EPS Growth
  • AMRX N/A
  • MTSR N/A
  • EPS
  • AMRX N/A
  • MTSR N/A
  • Revenue
  • AMRX $2,830,186,000.00
  • MTSR N/A
  • Revenue This Year
  • AMRX $9.84
  • MTSR N/A
  • Revenue Next Year
  • AMRX $7.33
  • MTSR N/A
  • P/E Ratio
  • AMRX N/A
  • MTSR N/A
  • Revenue Growth
  • AMRX 13.42
  • MTSR N/A
  • 52 Week Low
  • AMRX $6.32
  • MTSR $12.30
  • 52 Week High
  • AMRX $9.48
  • MTSR $37.99
  • Technical
  • Relative Strength Index (RSI)
  • AMRX 65.61
  • MTSR N/A
  • Support Level
  • AMRX $8.05
  • MTSR N/A
  • Resistance Level
  • AMRX $8.24
  • MTSR N/A
  • Average True Range (ATR)
  • AMRX 0.23
  • MTSR 0.00
  • MACD
  • AMRX 0.04
  • MTSR 0.00
  • Stochastic Oscillator
  • AMRX 93.15
  • MTSR 0.00

About AMRX Amneal Pharmaceuticals Inc.

Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE - It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.

About MTSR METSERA INC

Metsera Inc is a clinical-stage biotechnology company developing next-generation injectable and oral nutrient-stimulated hormone (NuSH) analog peptides to treat obesity, overweight, and related conditions. The Company has developed and is implementing proprietary methods and platform technologies to advance a broad, scalable, and combinable portfolio of injectable and oral NuSH analog peptides with the potential to address not only the limitations of approved therapies but also many of the anticipated limitations of next-generation therapies in development. The Company uses its proprietary MINT peptide library of NuSH analog peptides alongside its Half-life Augmentation by Lipid Optimization half-life extending platform.

Share on Social Networks: